Shocking Shift: Upper GI Cancers Now Claim More Lives Than Lung Cancer in Australia
A groundbreaking analysis from the Pancare Foundation has revealed a stark change in Australia's cancer landscape. For the first time in two decades, upper gastrointestinal (GI) cancers—encompassing pancreatic, liver, stomach, oesophagus, and biliary tract malignancies—have surpassed lung cancer as the leading cause of cancer-related deaths. In 2024 alone, these cancers accounted for 9,301 fatalities, edging out lung cancer's approximately 9,000 deaths, according to Australian Bureau of Statistics data. This development underscores the urgent need for heightened awareness, research, and funding in this under-resourced area.
Upper GI cancers collectively represent nearly one in five cancer deaths nationwide, yet they receive less than one in ten dollars of cancer research funding. Experts like Dr. Mark Buzza, Pancare's head of advocacy, highlight this disparity, calling for equitable investment to match the mortality burden.
Defining Upper GI Cancers: The Silent Killers of the Digestive System
Upper gastrointestinal cancers originate in the upper digestive tract. Pancreatic cancer affects the pancreas, an organ crucial for digestion and blood sugar regulation. Liver cancer typically arises in the liver, the body's metabolic powerhouse. Stomach cancer targets the stomach lining, while oesophageal cancer impacts the food pipe, and biliary cancers involve the bile ducts. These diseases often evade early detection due to vague symptoms like indigestion, back pain, or unexplained weight loss, leading to diagnosis at advanced stages.
The Upper Gastrointestinal Cancer Registry (UGICR), managed by Monash University's School of Public Health and Preventive Medicine, tracks over 12,000 annual diagnoses across these categories in Australia. Established to monitor care patterns and outcomes, the registry reveals significant variations in treatment, emphasizing the need for standardized protocols.
Alarming Mortality Statistics: A Data-Driven Wake-Up Call
Cancer Australia projects 169,759 new cancer cases in 2025, with 53,545 deaths. While lung cancer remains a top killer at around 8,994 deaths (16.8% of total), the combined upper GI toll tells a different story. Pancreatic cancer alone claims about 4,825 lives annually, liver cancer contributes significantly, and stomach cancer adds 2,740 new cases with high fatality.
- Pancreatic: 5-year survival ~14%
- Liver: Poor prognosis due to late detection
- Stomach: Incidence rising in certain demographics
Pancare's State of the Nation report forecasts 163,000 upper GI deaths from 2022-2035 without intervention, prompting calls for survival targets exceeding 50% by 2035.
Why the Surge? Unpacking Risk Factors and Trends
The rise stems from lifestyle shifts, aging populations, and stagnant screening. Obesity, alcohol, smoking, and chronic conditions like diabetes fuel pancreatic and liver cancers. Viral hepatitis drives liver cases, while H. pylori bacteria links to stomach cancer. Unlike lung cancer, where smoking cessation and screening have curbed deaths, upper GI lacks comparable tools.
Improvements in lung cancer management—targeted therapies and low-dose CT screening—have reduced its dominance. Meanwhile, upper GI survival lags: pancreatic at 14%, oesophageal below 25%.
Research Frontiers: Australian Universities Leading the Charge
Australian institutions are pivotal. QIMR Berghofer Medical Research Institute advances pancreatic and upper GI studies, exploring gut bacteria's role in tumour growth. Monash's UGICR provides real-world data, identifying care gaps.
Recent US Defense funding supports Hudson Institute's upper GI work, highlighting international collaboration. Universities like the University of Melbourne and University of Sydney contribute to clinical trials, including novel therapies.Explore research jobs in oncology
Funding Disparities: The Research Gap Hindering Progress
Despite high mortality, upper GI receives minimal funding. Pancare notes less than 10% of dollars versus 20% deaths. Professor Mehrdad Nikfarjam stresses innovative approaches beyond replicating successes in breast or prostate cancers.
Government and philanthropy must prioritize. The UGICR exemplifies efficient data use for quality improvement, but scaled funding could accelerate trials.Pancare Foundation
Patient Stories: The Human Cost and Hope
Carol Chevalier's tale exemplifies resilience. Misdiagnosed initially, scans revealed a pancreatic tumour, treated via Whipple procedure—a 13-hour surgery removing pancreas head, bile duct, and stomach part. Now enzyme-dependent, she advocates early vigilance.
Such stories fuel registries like UGICR, aiding personalized care.
Prevention and Early Detection Strategies
Key steps include:
- Maintain healthy weight, limit alcohol
- Hepatitis B vaccination, H. pylori testing
- Endoscopy for high-risk groups
Trials explore blood biomarkers and AI imaging for earlier diagnosis.
Photo by David Clode on Unsplash
Future Outlook: Trials, Innovations, and Calls to Action
Ongoing ASCO GI trials promise advances. Australian researchers target immunotherapy and precision medicine. By 2035, Pancare aims for 50% survival via research.
Academics, explore opportunities at university jobs or career advice. Engage via Rate My Professor.
For positions in cancer research, visit higher-ed-jobs/research-jobs, higher-ed-jobs/faculty, and post-a-job.